

HR 6431

Data Transparency and Drug Safety Act of 2022

Congress: 117 (2021–2023, Ended)

Chamber: House

Policy Area: Health

Introduced: Jan 19, 2022

Current Status: Referred to the Subcommittee on Health.

Latest Action: Referred to the Subcommittee on Health. (Jan 20, 2022)

Official Text: <https://www.congress.gov/bill/117th-congress/house-bill/6431>

Sponsor

Name: Rep. Schrier, Kim [D-WA-8]

Party: Democratic • **State:** WA • **Chamber:** House

Cosponsors (1 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Joyce, John [R-PA-13]	R · PA		Jan 19, 2022

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Jan 20, 2022

Subjects & Policy Tags

Policy Area:

Health

Related Bills

No related bills are listed.

Data Transparency and Drug Safety Act of 2022

This bill makes it a prohibited act under the Federal Food, Drug, and Cosmetic Act to destroy or falsify certain records pertaining to drugs regulated by the Food and Drug Administration (FDA).

Specifically, the bill prohibits falsifying, destroying, omitting, or removing records or information that (1) must be produced during the development or manufacture of a drug, (2) must be produced in an application for FDA approval for a drug or maintained after a drug is approved, or (3) is subject to FDA inspection.

A person (entity or individual) that violates this provision shall be subject to civil monetary penalties. The bill also provides for additional monetary penalties in instances where the violation is not sufficiently remedied after the responsible person has received written notice from the FDA of the violation.

Actions Timeline

- **Jan 20, 2022:** Referred to the Subcommittee on Health.
- **Jan 19, 2022:** Introduced in House
- **Jan 19, 2022:** Referred to the House Committee on Energy and Commerce.